Vertex Pharmaceuticals (VRTX) Preferred Stock Liabilities (2009 - 2010)
Vertex Pharmaceuticals (VRTX) posted Preferred Stock Liabilities of $11.2 million for Q3 2010, down 21.89% on a QoQ basis from $14.3 million in Q2 2010.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Preferred Stock Liabilities (2009 - 2010) Analysis & Trends
Vertex Pharmaceuticals has reported Preferred Stock Liabilities for 2 years, with the latest figure at $11.2 million in Q3 2010.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $11.2 million in Q3 2010; TTM through Sep 2010 was $11.2 million, a N/A change from a year earlier, with the FY2009 full-year figure at $10.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $11.2 million for Q3 2010 at Vertex Pharmaceuticals, down from $14.3 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $14.3 million in Q2 2010, with the low at $10.5 million in Q4 2009.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2010 | 11.17 Mn |
| Jun 30, 2010 | 14.30 Mn |
| Dec 31, 2009 | 10.45 Mn |